Amber Therapeutics is pioneering the development of the Picostim™ System, an innovative neuromodulation therapy designed to treat women suffering from mixed urinary incontinence (MUI). This fully implantable device targets the pudendal nerve, utilizing a dual-function approach that allows it to both stimulate and sense physiological responses. The therapy is personalized and adaptive, meaning it can dynamically adjust its operation based on the individual’s needs and specific events, marking a significant advancement over existing treatments that typically address either urge or stress incontinence separately.

The Picostim system's foundation lies in its origins as a cranial implant for deep brain stimulation, which has been further enhanced with the DyNeuMo firmware to enable fully adaptive therapy capabilities. This technology is currently being validated through various first-in-human trials, including the AURA-2 study, which has shown promising results in terms of safety and clinical efficacy. By focusing on restoring normal physiological function, Amber Therapeutics aims to transform the quality of life for millions of women affected by urinary incontinence, addressing a critical area of unmet clinical need.

United Kingdom

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally restore normal physiological function in women suffering with mixed urinary incontinence. The company's first therapy, Amber UI, is an intelligent closed-loop bioelectrical therapy for urge and mixed urinary incontinence. The startup has also acquired Bioinduction, a fellow U.K.-based company and the maker of the Picostim DyNeuMo platform.

Amber Therapeutics

Company Details